Results 1 to 10 of about 2,386,530 (346)

PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells [PDF]

Immunity, 2018
CD4+ T cell differentiation into multiple T helper (Th) cell lineages is critical for optimal adaptive immune responses. This report identifies an intrinsic mechanism by which programmed death-1 receptor (PD-1) signaling imparted regulatory phenotype to ...
Amarnath, Shoba, Berlinguer-Palmini, Rolando, Bogyo, Matthew, Eckhaus, Michael A., Edgington-Mitchell, Laura, Felizardo, Tania C., Flomerfelt, Francis A., Fowler, Daniel H., Gangaplara, Arunakumar, Knight, David, Laurence, Arian, Liniany, Lukasz P., Mallett, Grace, Martinez-Fabregas, Jonathan, Samsel, Leigh A., Shevach, Ethan M., Stathopoulou, Chaido, van Kasteren, Sander I., Watts, Colin, Yim, Joshua J., Zhu, Jinfang   +20 more
core   +3 more sources

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy

Frontiers in Immunology, 2018
Blockade of programmed death 1 (PD-1) protein and its ligand programmed death ligand 1 (PD-L1) has been used as cancer immunotherapy in recent years, with the blockade of PD-1 being more widely used than blockade of PD-L1. PD-1 and PD-L1 blockade therapy
Yiming Wang, Rena Ma, Fang Liu, Seul A. Lee, Li Zhang   +4 more
doaj   +2 more sources

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction

Journal of Medicinal Chemistry, 2021
We describe a new class of potent PD-L1/PD-1 inhibitors based on a terphenyl scaffold that is derived from the rigidified biphenyl-inspired structure.
Damian Muszak, Ewa Surmiak, Jacek Plewka, K. Magiera-Mularz, Justyna Kocik-Krol, B. Musielak, D. Sala, Radosław Kitel, M. Stec, K. Węglarczyk, M. Siedlar, A. Dömling, L. Skalniak, T. Holak   +13 more
semanticscholar   +1 more source

Emerging role of the immunotherapy in treatment of breast cancer

SVU - International Journal of Medical Sciences, 2021
Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated ...
Nagwa Abd El-Sadek Ahmed*, Maisa Hashem Mohammed   +1 more
doaj   +1 more source

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

Journal of Clinical Oncology, 2023
PURPOSE Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti–programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation.
P. Ascierto, E. Lipson, R. Dummer, J. Larkin, G. Long, R. Sanborn, V. Chiarion-Sileni, B. Dréno, S. Dalle, D. Schadendorf, M. Callahan, M. Nyakas, V. Atkinson, C. Gomez-Roca, N. Yamazaki, H. Tawbi, Naomey Sarkis, D. Warad, S. Dolfi, Priyam Mitra, S. Suryawanshi, J. Grob   +21 more
semanticscholar   +1 more source

Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.

Acta Biomaterialia, 2022
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, including colorectal cancer. However, the efficacy of PD-1/PD-
Yuchen Xiao, Tianchuan Zhu, Qi Zeng, Qingqin Tan, Guanmin Jiang, Xi Huang   +5 more
semanticscholar   +1 more source

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients [PDF]

Journal of Pathology and Translational Medicine, 2017
Background Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells.
Jiheun Han, Yongkil Hong, Youn Soo Lee
doaj   +1 more source

Expression and Significance of PD-1, PD-L1 and PD-L2 in T Cell Subsets and Myeloma Cells in Newly Diagnosed Multiple Myeloma Patients

Zhongliu Fangzhi Yanjiu, 2022
Objective To investigate the expression of PD-1 and PD-L1/2 in T cell subsets and myeloma cells in the bone marrow from newly diagnosed multiple myeloma (NDMM) patients and their relation with clinical features.
MA Yinjuan, YANG Ke, YANG Xiaying, BAI Jiaofeng, BAI Hai, WU Tao, FU Lihua, JIANG Junfeng, PAN Yaozhu   +8 more
doaj   +1 more source

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy

Gut, 2021
Objective Programmed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising for late-stage lung cancer treatment, however, the response rate needs to be improved.
Jumin Huang, Di Liu, Yuwei Wang, Liang Liu, Jian Li, Jing Yuan, Zhihong Jiang, Ze-bo Jiang, W. Hsiao, Haizhou Liu, Imran Khan, Ying Xie, Jianlin Wu, Ya-Jia Xie, Yizhong Zhang, Yu Fu, Junyi Liao, Wenjun Wang, Huanling Lai, A-Xi Shi, Jun Cai, Lianxiang Luo, Run-Ze Li, Xiaojun Yao, Xing-Xing Fan, Qibiao Wu, Zhongqiu Liu, Pei-yu Yan, Jingguang Lu, Ming-rong Yang, Lin Wang, Yabing Cao, Hong Wei, E. Leung   +33 more
semanticscholar   +1 more source

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma

Journal for ImmunoTherapy of Cancer, 2022
Background Programmed cell death 1 (PD-1) blockade induces tumor regression in patients with advanced esophageal squamous cell carcinoma (ESCC); however, little is known about the efficacy of PD-1 blockade as neoadjuvant therapy in resectable ESCC.
Weixiong Yang, Xiangbin Xing, S. Yeung, Siyu Wang, Wenfang Chen, Y. Bao, Fang Wang, S. Feng, F. Peng, Xiaoyan Wang, Shuling Chen, M. He, Ningfang Zhang, Honglei Wang, B. Zeng, Zhenguo Liu, B. Kidane, C. Seder, K. Koyanagi, Y. Shargall, Honghe Luo, S. Peng, Chao Cheng   +22 more
semanticscholar   +1 more source